PKM2 inhibitor (compound 3k): Selective Disruption of Tumor Glycolysis

Executive Summary: PKM2 inhibitor (compound 3k), supplied by APExBIO, is a small molecule that selectively inhibits pyruvate kinase M2 (PKM2), a master regulator of glycolysis in cancer and immune cells (source: product_spec). It exhibits an IC50 of 2.95 μM against PKM2 enzyme activity and demonstrates nanomolar antiproliferative effects on several cancer cell lines, including HCT116, HeLa, and H1299 (source: workflow_recommendation). Compound 3k reduces tumor growth in vivo and modulates inflammatory macrophage polarization via PKM2-dependent metabolic reprogramming (source: paper). The compound shows higher selectivity for tumor cells over normal cells, and in animal models, treatment with 5 mg/kg every two days for 31 days reduced tumor volume without major toxicity (source: workflow_recommendation).

Biological Rationale

Pyruvate kinase M2 (PKM2) catalyzes the final step of glycolysis and is preferentially expressed in proliferating cells, including cancer cells and activated pro-inflammatory macrophages (source: paper). In tumors, upregulated PKM2 activity supports aerobic glycolysis (the Warburg effect), facilitating rapid ATP and biomass production required for cell proliferation. In immune cells, PKM2 drives pro-inflammatory M1 macrophage polarization through metabolic reprogramming (source: internal_article). Inhibiting PKM2 thus represents a rational strategy to selectively target tumor metabolism and modulate immune responses.

Mechanism of Action of PKM2 inhibitor (compound 3k)

PKM2 inhibitor (compound 3k) is a selective small molecule that binds to the PKM2 isoform, inhibiting its enzymatic activity with an in vitro IC50 of 2.95 μM (source: product_spec). By blocking PKM2, compound 3k disrupts aerobic glycolysis, leading to decreased lactate production and ATP generation in cancer cells. This metabolic stress triggers autophagic cell death and suppresses cell proliferation (source: internal_article). In immune cells, PKM2 inhibition skews macrophage polarization away from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype, as shown by metabolic, phenotypic, and cytokine readouts in severe acute pancreatitis models (source: paper). The selectivity of compound 3k for PKM2 over other pyruvate kinase isoforms underpins its tumor cell specificity and limits off-target effects.

Evidence & Benchmarks

• Compound 3k inhibits recombinant PKM2 enzyme activity with an IC50 of 2.95 μM (source: product_spec).
• Demonstrated antiproliferative activity in vitro against HCT116 (IC50 = 0.18 μM), HeLa (IC50 = 0.29 μM), and H1299 (IC50 = 1.56 μM) cancer cell lines (source: internal_article).
• Shows markedly lower cytotoxicity toward normal BEAS-2B cells compared to tumor cells (source: internal_article).
• In vivo, oral administration at 5 mg/kg every two days for 31 days reduced SK-OV-3 ovarian tumor xenograft volume and weight in BALB/c nude mice without major organ toxicity or significant weight loss (source: internal_article).
• In severe acute pancreatitis mouse models, PKM2 inhibitor treatment partially reversed the protective effect of USP7 knockdown, confirming PKM2's role in macrophage polarization (source: paper).

Compared to the article "PKM2 Inhibitor (Compound 3k): Selective Pyruvate Kinase M..." (read more), this review provides updated data on in vivo selectivity and PKM2-dependent immune modulation, clarifying translational implications beyond oncology.

For a mechanistic perspective, see "Rewiring Cancer and Immune Metabolism: Mechanistic Insigh..." (read more), which this article extends by integrating recent findings on macrophage polarization in inflammatory models.

Applications, Limits & Misconceptions

PKM2 inhibitor (compound 3k) is validated in preclinical cancer models as a selective antiproliferative agent for cancer cells and as a tool to modulate macrophage-driven inflammation (sources: product_spec; paper). Its application in ovarian cancer therapy is supported by xenograft studies, and its tumor cell-specific PKM2 targeting enables research on metabolic vulnerabilities. However, clinical trials in humans have not yet been reported. Use in other inflammatory or metabolic diseases remains a hypothesis and is not yet substantiated by experimental data (workflow_recommendation).

Common Pitfalls or Misconceptions

• Compound 3k is not active against all PK isoforms; it is selective for PKM2 (source: product_spec).
• In vivo efficacy and safety are established only in mouse models; human translation is untested (source: internal_article).
• Compound 3k is insoluble in water and ethanol; DMSO is required for solution preparation (source: product_spec).
• Long-term solution stability is not established; solutions should be freshly prepared for use (workflow_recommendation).
• Effects on non-cancerous or non-immune tissues are incompletely characterized (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• cancer cell proliferation assay | IC50 = 0.18–1.56 μM | HCT116, HeLa, H1299 | benchmarked for antiproliferative efficacy | internal_article
• PKM2 enzymatic inhibition | IC50 = 2.95 μM | recombinant enzyme | direct PKM2 activity measurement | product_spec
• in vivo tumor xenograft | 5 mg/kg, oral, every 2 days, 31 days | BALB/c nude mice with SK-OV-3 tumors | assesses antitumor efficacy and toxicity | internal_article
• solubility | ≥34.5 mg/mL in DMSO (warmed) | compound prep | ensures assay compatibility | product_spec
• storage | -20°C (solid), short-term in DMSO | compound handling | preserves stability | product_spec
• pancreatitis mouse model | 25 mg/kg, i.p., rescue | SAP, USP7 knockdown | tests PKM2 dependency in immune modulation | paper

Conclusion & Outlook

PKM2 inhibitor (compound 3k) represents a robust tool for dissecting metabolic dependencies in cancer and inflammatory models. Its dual role as a cancer cell metabolism inhibitor and modulator of immune cell phenotype is well supported by preclinical evidence (sources: paper; product_spec). Future work should focus on translating these findings to clinical settings and expanding mechanistic insights into non-oncologic diseases where PKM2 plays a role. The selective PKM2 inhibitor from APExBIO is poised to accelerate research into tumor cell-specific metabolic targeting and immune modulation.

For further mechanistic background, see "USP7–PKM2 Axis Modulates Macrophage Polarization in SAP" (read more), which this article updates by providing compound-specific interventional data.